Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC)

[1] Kamat AM(2013)ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers Eur Urol 63 4-15

[2] Hegarty PK(2017)Bladder cancer incidence and mortality: a global overview and recent trends Eur Urol 71 96-108

[3] Gee JR(2003)Adherence to surveillance among patients with superficial bladder cancer J Natl Cancer Inst 95 588-597

[4] Clark PE(2016)Comparison of guidelines on non-muscle invasive bladder cancer. (EAU, CUA, AUA, NCCN, NICE) Bladder Cancer 2 27-36

[5] Svatek RS(2017)Multicenter analysis of the oncological positivity on restaging resection (Re-Turbt) of urothelial non-muscle-invasive bladder cancer ARC J Urol 2 25-30

[6] Hegarty N(2016)Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline J Urol 196 1021-1029

[7] Antoni S(1987)A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chron Dis 40 373-383

[8] Ferlay J(2017)Guideline of guidelines: non-muscle-invasive bladder cancer BJU Int 119 371-380

[9] Soerjomataram I(2016)CCAFU french national guidelines 2016–2018 on bladder cancer Prog Urol 27 S67-S91

[10] Znaor A(2016)Bladder cancer: low adherence to guidelines in non-muscle-invasive disease Nat Rev Urol 13 570-571

[1] Kamat AM(2013)ICUD-EAU international consultation on bladder cancer 2012: screening, diagnosis, and molecular markers Eur Urol 63 4-15

[2] Hegarty PK(2017)Bladder cancer incidence and mortality: a global overview and recent trends Eur Urol 71 96-108

[3] Gee JR(2003)Adherence to surveillance among patients with superficial bladder cancer J Natl Cancer Inst 95 588-597

[4] Clark PE(2016)Comparison of guidelines on non-muscle invasive bladder cancer. (EAU, CUA, AUA, NCCN, NICE) Bladder Cancer 2 27-36

[5] Svatek RS(2017)Multicenter analysis of the oncological positivity on restaging resection (Re-Turbt) of urothelial non-muscle-invasive bladder cancer ARC J Urol 2 25-30

[6] Hegarty N(2016)Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline J Urol 196 1021-1029

[7] Antoni S(1987)A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chron Dis 40 373-383

[8] Ferlay J(2017)Guideline of guidelines: non-muscle-invasive bladder cancer BJU Int 119 371-380

[9] Soerjomataram I(2016)CCAFU french national guidelines 2016–2018 on bladder cancer Prog Urol 27 S67-S91

[10] Znaor A(2016)Bladder cancer: low adherence to guidelines in non-muscle-invasive disease Nat Rev Urol 13 570-571